Last $2.70 USD
Change Today +0.05 / 1.89%
Volume 94.8K
BTX On Other Exchanges
Symbol
Exchange
BTX is not on other exchanges.
As of 8:04 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

biotime inc (BTX) Snapshot

Open
$2.65
Previous Close
$2.65
Day High
$2.82
Day Low
$2.65
52 Week High
07/16/13 - $4.30
52 Week Low
05/12/14 - $2.21
Market Cap
194.8M
Average Volume 10 Days
235.8K
EPS TTM
$-0.59
Shares Outstanding
72.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTIME INC (BTX)

biotime inc (BTX) Related Businessweek News

No Related Businessweek News Found

biotime inc (BTX) Details

BioTime, Inc., a biotechnology company, is engaged in the research and product development in the field of regenerative medicine. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, cGMP-capable human embryonic stem cell lines, and differentiation kits, as well as offers Hextend, a blood plasma volume expander to treat hypovolemia in surgery, emergency trauma treatment, and other applications. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; and stem cell-based therapies for retinal and neurological disorders. It also develops HyStem hydrogels, such as ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and Premvia, a hydrogel formulation to manage wounds, as well as PanC-Dx, a non-invasive cancer products for use in detecting breast, bladder, and lung cancers. In addition, the company markets GeneCards, a human gene database. Further, it is developing an integrated database suite to complement GeneCards that would include the LifeMap database of embryonic development, stem cell research, and regenerative medicine, as well as MalaCards, the human disease database. Additionally, the company develops cell based therapeutic products for diseases, such as neurological disorders, age related macular degeneration, orthopedic disorders, and cardiovascular disease and related ischemic disorders. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

106 Employees
Last Reported Date: 03/17/14
Founded in 1990

biotime inc (BTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $745.3K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $550.1K
Chief Commercial Officer
Total Annual Compensation: $315.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $104.2K
Compensation as of Fiscal Year 2013.

biotime inc (BTX) Key Developments

BioTime, Inc. Announces Auditor Changes

BioTime, Inc. announced that Rothstein Kass is no longer providing accounting and audit services and on June 30, 2014 Rothstein Kass resigned as the independent registered public accounting firm. On July 7, 2014, the board of directors approved the engagement of OUM & Co. LLP as the new independent registered public accounting firm.

BioTime, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 09:00 AM

BioTime, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 09:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Michael D. West, Chief Executive Officer, President and Director.

LifeMap Sciences Seeks Financing

The initial financing tranche for LifeMap Sciences, Inc. will be provided to LifeMap Sciences by BioTime, Inc. (AMEX:BTX) through the purchase of additional shares of LifeMap Sciences common stock. BioTime may acquire additional LifeMap Sciences common stock for cash or in exchange for BioTime common shares when product development milestones are met and if funding is not provided through other sources.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTX:US $2.70 USD +0.05

BTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $0.08 USD +0.0002
Athersys Inc $1.71 USD +0.02
Cytori Therapeutics Inc $2.22 USD +0.01
Fibrocell Science Inc $3.22 USD +0.02
NeoStem Inc $6.01 USD +0.15
View Industry Companies
 

Industry Analysis

BTX

Industry Average

Valuation BTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.2x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 32.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIME INC, please visit www.biotimeinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.